CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
about
Pancreatic cancer stem cell markers and exosomes - the incentive pushCurrent Stem Cell Biomarkers and Their Functional Mechanisms in Prostate CancerThe role of CD44 in epithelial-mesenchymal transition and cancer developmentManagement of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survivalCD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating CellsDevelopment of cancer-initiating cells and immortalized cells with genomic instability.Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5.SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression.Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation.Ionizing radiation promotes advanced malignant traits in nasopharyngeal carcinoma via activation of epithelial-mesenchymal transition and the cancer stem cell phenotypeInduction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.The Role of CD44 in Disease Pathophysiology and Targeted Treatment.Opportunities and challenges of radiotherapy for treating cancer.Prostate cancer stem cells: from theory to practice.Prostate Cancer Stem Cells: Viewing Signaling Cascades at a Finer Resolution.Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance.Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis.Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts.CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence.CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells.Advances in prostate cancer research and treatment.Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.The CD44-Mediated Uptake of Hyaluronic Acid-Based Carriers in Macrophages.Intratumoral heterogeneity of CD44v6 in rectal cancer.The biology and role of CD44 in cancer progression: therapeutic implications.Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo
P2860
Q26741215-F7A973FE-F935-4D15-AF7A-B87D8F78B388Q26742062-79CF0BD6-D700-446A-8259-F596DC10D5A4Q26771509-6D90A60E-5380-44ED-9CA2-F380674821F1Q26853543-200E2DC2-DA15-405C-9634-11AD4777AB89Q28084610-9BC2182B-4602-4AF6-9E7A-4A801E1808E8Q35205699-982CC371-F5EB-4F92-B1F0-5746ECF22786Q35380267-A48C5136-6F33-4227-BE7A-19931D1E059AQ35562215-36B17592-CC0C-435F-8E38-6F14DE29A0ECQ36535407-BF625EC8-37CC-4E42-91FB-1830A185A06CQ36878785-92D2A977-5636-4CE1-8E97-2CB050DFA45BQ36983775-46634D89-7C20-4AEC-91DC-E81890FF23DEQ37615676-CCD136D4-61D6-4D9B-8BC9-C7360B210136Q38466771-E92ED9B0-6E4D-4902-AA29-F14E9AE3CD86Q38539957-11CCEA81-1337-482D-A601-095CD3D96211Q38668605-69142F87-BB3B-437D-8F26-2BED39623531Q38723375-41A97C59-904F-462C-8256-ADA30E287B6EQ38805489-5A12DBA9-11D5-4C3C-96F4-4E5074C9E62EQ38845190-1C8A72A8-E063-4483-81B9-57F55BCCDEB3Q38872768-B225107A-52CF-467C-94FF-C1EAA5D63A3CQ38889921-56BB1232-8AF9-42C4-9A20-28DA15444712Q41294963-47C9B4E3-BF2D-4231-A3B1-65E649C361F9Q41849010-DBF88891-5801-4459-80C2-85B02CB25BC2Q42084382-E0BBE49D-9379-435A-8E86-18D6FB5B6B6DQ42113453-52FCF81A-3E35-454A-815A-744D62D43273Q43869209-744F0DEC-7CF0-44B8-8932-02B7992508D7Q44262180-640CF929-1CE7-443E-BDD3-9E5F430841FCQ51251704-C67EAC9A-6771-4CC2-8FAD-52830DF713BCQ51554860-2F46BA38-7E5E-4B69-B72B-AC1548B44F60Q54110894-618A0364-0864-4DA8-9007-217E246A17BCQ55309145-0F55EA18-7C1E-4477-8CA6-BE907C74C6C3Q59136173-3DFC9F37-5607-4998-8E61-3CD7928BA10F
P2860
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@ast
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@en
type
label
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@ast
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@en
prefLabel
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@ast
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@en
P2093
P2860
P356
P1433
P1476
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
@en
P2093
Jing L Hao
John H Kearsley
Joseph Bucci
Julia Beretov
Paul J Cozzi
Peter H Graham
Sarah Shigdar
Warick J Delprado
P2860
P304
P356
10.1002/PROS.22775
P577
2014-02-12T00:00:00Z